The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Amphastar’s 2020 financial results included its best ever quarter and a different revenue pattern from most pharma and generic companies. Its evolving product mix and marketing campaigns were two reasons for its performance.

Takeda's acquisition of Shire fueled the company into a top 10 pharma company in the latest Scrip 100 rankings, as other mega-mergers are set to shape the leaderboard in the future. 

Given the ongoing election challenges in the US, China has yet to officially congratulate Joe Biden as the next US president, although many world leaders are already hailing a reset in US foreign policy. Many are wondering if this and other moves indicate a quiet internal shift for China's high tech and life sciences sectors, just days after Beijing concluded a high-level plenary meeting outlining its priorities for the next five years.